OTCs Could Save Billions In Respiratory Infection Treatment Costs – Study
This article was originally published in The Tan Sheet
Executive Summary
OTC drug therapy during the early stages of upper respiratory infections (URIs) could save up to $4.75 bil. annually in the U.S., according to an analysis conducted by Martin Lipsky, MD, Northwestern University, Feinberg School of Medicine, et al
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning